Global Cardiovascular Application Market: Information by Device (Cardiac Monitors, Cardiac Pacemakers And Cardiac Defibrillators), End User (Hospitals, Cardiac Care Centers, Ambulatory Centers & Home Care and Academic Centers) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027
ID: MRFR/MED/3817-CR | July 2019 | Region: Global | 138 pages
MARKET OVERVIEW
Nowadays cardiac disease has become critical and life-threatening and has shown its increasing prevalence over the global landscape. Cardiovascular disease includes disorders of heart or blood vessels and includes some conditions like hypertension and hyperlipidemia. In the current cardiovascular application market 2021, there are a number of factors and trends which provide major impetus to the cardiovascular application market size. There is increased awareness in relation to the serious impact of life-threatening heart diseases on human health. The development in the minimal invasion therapeutic structure has encouraged the usage of good equipment. An increase in demand for image guidance has propelled its growth. The trend of today’s lifestyle may lead to a significant proportion of the globalised population developing cardiovascular diseases. Persons at risk of undergoing this disease may face obesity, increased blood pressure levels, lipids, etc. increased research and novel therapeutics in this field have contributed substantially to increased medications.
COVID 19 ANALYSIS
Some of the guidelines given by the government help in understanding the severity of the effect of COVID on a variety of therapies and in assessing the recovery of device markets in terms of associated procedure volume. The pandemic of COVID 19 has made the person suffer from more complications like myocardial injury, arrhythmias, etc. clinical trials were either halted or was postponed. Cardiovascular application market 2021 showed degradation where the patient’s enrollment was paused for certain therapies.
The government recommended certain guidelines for the management of cardiology patients. Guidelines were also put forward on community-based care. This pandemic made more than 50% of people suffer from more chronic medical illness. It has been making a significant investment for the treatment.
REGIONAL ANALYSIS
Revenue of USD 21.89 billion was generated by North America and occupied a dominant region in the overall market. Prevalence of risky cardiovascular disease along with the new product was launched in the region which drove the cardiovascular application market growth. Due to the expansion of indispensable income across the Asia Pacific region. Prevalence of this disease from key countries and the increasing status of cardiovascular disease is the leading cause and is also anticipated to drive the market.
Europe shows significant growth because this disease causes significant death across the region.
MARKET DYNAMICS
Drivers- Increased awareness with respect to health and a corresponding increase in the launching of products are major drivers of the market. A multifaceted approach like a demand for effective therapeutics. The Discovery of several advanced drugs by the competitors increases the crowd of the market. An increase in efficiency of cheaper generics is the major driving factor of the market. A drug like Eliquis is the risk of reducer drug in the cardiovascular app market share.
Opportunities- an initiative was taken by cardiovascular innovations and applications, which made the business in effortless decision taking and providing sufficient information. All these factors gave huge opportunities for the business to have proper growth. Differentiating maximizing return in investment provides great opportunities for the company to enter into this field.
Restraints- Factors like drug recall and biocompatibility issue restraints the growth of the market. If in case approval of the novel drugs takes a lot of time, then the lucrative growth is surely going to be hampered as its delivery time will also be delayed. Rising heart costs are the major costs that are impacting healthcare costs.
Challenges- The advancement of safety and remote monitoring in the devices creates growth opportunities for the market. The feasibility of new investments is assessed from the overall research conclusion offered.
Cumulative growth- some kind of investment is made to cater for the growth of the market and gain its momentum in this forecast period. The prevalence of major manufacturers and the regulatory scenario is responsible for lucrative growth.
SEGMENT OVERVIEW
Type- On this basis the market is segmented into hypertensive, antihyperlipidemic, anticoagulants, antiplatelet drugs and many others. Anticoagulants play a major dominant share in the market. This segment is expected to grow at a high CAGR due to the presence of Eliquis. Other segments of the type contribute to the steady rate. Antihypertensive is expected to cover the second-highest share of the market after anticoagulant.
Technology- with the advancement of technology, its application was used in the cardiovascular field. AI algorithms are being used to detect arrhythmias and give alerts to patients using smart devices. Use a TAVR as a good valve replacement. Wearable technologies have helped both consumers and professionals to monitor the patient’s health in a better way. The new EP technologies have helped physicians to speed up the transfer of how to gain knowledge and access the technology. The advancement of technology has provided the market with ongoing expansion.
Services- some of the hospitals have adopted digital solutions which enable the provider to diagnose better, which remotely treats and reminds patients about treatment and provides management of high-risk care.
VALUE CHAIN ANALYSIS
The value chain analysis of the cardiovascular market is evolving. Value chain growth by direct or indirect sales channels, insights into the traders, distributors and dealers present in this market environment.
COMPETITIVE LANDSCAPE
Key companies in the market show a strong portfolio, key strategic decisions and dominance of market share globally. Countries with high cardiovascular application market share include the UK, France and Germany contributing to the entire European market. Robust growth due to increasing prevalence in the market was seen in the regions of Latin America. In this forecast period, steady growth was marked in the Middle East and Africa.
Some of the companies are Pfizer Inc, Bayer AG, Sanofi, Novartis AG, Merck and Co Inc, Janssen Pharmaceuticals Inc, Gilead Sciences Inc, etc.
RECENT DEVELOPMENTS
The approval of the Prevention of Venous Thromboembolism in ill patients was announced by the Food and Drug Administration. These patients must not be at higher risk of bleeding for Janssen Pharmaceuticals Inc S product offerings for rivaroxaban.
Novartis AG and Black Stone’s Life Sciences gave the approval for the launching of Anthos Therapeutics for the development of cardiovascular drugs.
Launching of Valsartan - Sacubitril for the treatment of congestive heart failure was announced by Natco Pharma.
Launching of MyCareLink Heart mobile app by Medtronics which links the list of pacemakers which has direct communication with the patient’s cell phone.
For coronary perforation, Biotronik announced the launching of PK Papyrus Covered Coronary Stent, at times of emergency.
REPORT OVERVIEW
On the basis of advanced technologies, awareness and growth in the drug market were observed. The report shows extensive analysis of the scenario of the competitive landscape and market dynamics. Prevalence of disease in the market in specific countries, insights about industry development and reimbursement and advances in novel therapeutics, etc. key strategies by market leaders and its so maintained company profiles show about cardiovascular application market growth.
The report tells us about the respiratory failure of the patients during the times of COVID 19. This report provides an overview of the cardiovascular market. It provides economic factors, marketing trends that influence the global market. obal market. The enterprise changing elements for expansion of market segments have been reported. This report will help the customers to make a strategic decision for business enterprises. It also gives an entire forecast by means of product, application and region.
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2027: Significant Value |
| CAGR | 2020-2027: Substantial CAGR |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Device, End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Pfizer Inc, Bayer AG, Sanofi, Novartis AG, Merck and Co Inc, Janssen Pharmaceuticals Inc, Gilead Sciences Inc, etc. |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
Cardiovascular application market is projected to grow at a 7.24% CAGR between 2020-2027.
The Americas is expected to dominate the cardiovascular application market.
Cardiovascular application market is predicted to touch USD 36, 730.5 million by 2023.
End use industries of the cardiovascular application market include home care, ambulatory centers, academic institutes, and cardiac care centers.
Strict regulatory guidelines may limit the cardiovascular application market growth.
1 Report Prologue
2 Market Introduction
2.1 Definition 17
2.2 Scope Of Study 17
2.3 Research Objective 17
2.4 Assumptions & Limitations 18
2.4.1 Assumptions 18
2.4.2 Limitations 18
2.5 Market Structure 18
3 Research Methodology
3.1 Primary Research Methodology 20
3.2 Secondary Research Methodology 21
3.3 Market Share Analysis 21
3.4 Market Pricing Approach
4 Market Factor Analysis
4.1 Value Chain Analysis 23
4.1.1 R&D And Designing 23
4.1.2 Manufacturing 24
4.1.3 Distribution & Sales 24
4.1.4 Post-Sales Monitoring 24
4.2 Porter’s Five Forces Model 25
4.2.1 Bargaining Power Of Suppliers 25
4.2.2 Bargaining Power Of Buyers 26
4.2.3 Threat Of New Entrants 26
4.2.4 Threat Of Substitutes 26
4.2.5 Intensity Of Rivalry 26
4.3 Demand & Supply: Gap Analysis 27
4.4 Pricing Analysis 27
5 Market Dynamics
5.1 Introduction 28
5.2 Drivers 29
5.2.1 Increasing Prevalence Of Cardiovascular Diseases 29
5.2.2 Favourable Reimbursement Policies 30
5.2.3 Increasing Geriatric Population 31
5.3 Restraints 32
5.3.1 Strict Regulatory Guidelines 32
5.4 Mega Trends 33
5.5 Macroeconomic Indicators 33
6 Global Cardiovascular Application Market By Device
6.1 Introduction 35
6.2 Cardiac Monitors 36
6.3 Cardiac Pacemakers 37
6.4 Cardiac Defibrillators
7 Global Cardiovascular Application Market By End User
7.1 Introduction 40
7.2 Hospitals 41
7.3 Cardiac Care Centers 42
7.4 Ambulatory Centers & Home Care 43
7.5 Academic Centers
8 Global Cardiovascular Application Market By Region
8.1 Introduction 45
8.2 Americas 47
8.2.1 North America 50
8.2.1.1 U.S. 53
8.2.1.2 Canada 56
8.2.2 South America 58
8.3 Europe 61
8.3.1 Western Europe 64
8.3.1.1 Germany 68
8.3.1.2 France 70
8.3.1.3 U.K. 73
8.3.1.4 Italy 75
8.3.1.5 Spain 78
8.3.1.6 Rest Of Western Europe 80
8.3.2 Eastern Europe 83
8.4 Asia Pacific 86
8.4.1 Japan 90
8.4.2 China 92
8.4.3 India 95
8.4.4 Australia 97
8.4.5 Republic Of Korea 100
8.4.6 Rest Of Asia Pacific 102
8.5 Middle East & Africa 105
8.5.1 United Arab Emirates 109
8.5.2 Saudi Arabia 111
8.5.3 Oman 114
8.5.4 Kuwait 116
8.5.5 Qatar 119
8.5.6 Rest Of Middle East & Africa 121
9 Company Landscape
9.1 Introduction 125
9.2 Company Share Analysis 125
9.3 Key Developments 126
10 Company Profiles
10.1 Abbott 128
10.1.1 Company Overview 128
10.1.2 Financials 128
10.1.3 Products 128
10.1.4 Strategy 128
10.1.5 Key Developments 128
10.2 General Electric Company 129
10.2.1 Company Overview 129
10.2.2 Financials 129
10.2.3 Products 129
10.2.4 Strategy 129
10.2.5 Key Developments 129
10.3 Medtronic 130
10.3.1 Company Overview 130
10.3.2 Financials 130
10.3.3 Products 130
10.3.4 Strategy 130
10.3.5 Key Developments 130
10.4 Boston Scientific Corporation 131
10.4.1 Company Overview 131
10.4.2 Financials 131
10.4.3 Products 131
10.4.4 Strategy 131
10.4.5 Key Developments 131
10.5 Koninklijke Philips N.V 132
10.5.1 Company Overview 132
10.5.2 Financials 132
10.5.3 Products 132
10.5.4 Strategy 132
10.5.5 Key Developments 132
10.6 Terumo 133
10.6.1 Company Overview 133
10.6.2 Financials 133
10.6.3 Products 133
10.6.4 Strategy 133
10.6.5 Key Developments 133
10.7 Stryker Corporation 134
10.7.1 Company Overview 134
10.7.2 Financials 134
10.7.3 Products 134
10.7.4 Strategy 134
10.7.5 Key Developments 134
11 Conclusion
11.1 Key Findings 135
11.1.1 CEO’s Viewpoint 135
11.1.2 Unmet Needs 135
11.1.3 Key Companies To Watch
12 Appendix
12.1 Discussion Blue Print 136
12.2 References
13 List Of Tables
TABLE 1 PRIMARY INTERVIEWS 20
TABLE 2 GLOBAL CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 35
TABLE 3 GLOBAL CARDIOVASCULAR APPLICATION MARKET FOR CARDIAC MONITORS BY REGION,
2020 TO 2027 (USD MILLION) 36
TABLE 4 GLOBAL CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 36
TABLE 5 GLOBAL CARDIOVASCULAR APPLICATION MARKET FOR CARDIAC MONITORS BY REGION,
2020 TO 2027 (USD MILLION) 37
TABLE 6 GLOBAL CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 37
TABLE 7 GLOBAL IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 38
TABLE 8 GLOBAL CARDIOVASCULAR APPLICATION MARKET FOR CARDIAC DEFIBRILLATORS BY REGION,
2020 TO 2027 (USD MILLION) 38
TABLE 9 GLOBAL CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 39
TABLE 10 GLOBAL CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 41
TABLE 11 GLOBAL CARDIOVASCULAR APPLICATION MARKET FOR HOSPITALS BY REGION,
2020 TO 2027 (USD MILLION) 41
TABLE 12 GLOBAL CARDIOVASCULAR APPLICATION MARKET FOR CARDIAC CARE CENTERS BY REGION,
2020 TO 2027 (USD MILLION) 42
TABLE 13 GLOBAL CARDIOVASCULAR APPLICATION MARKET FOR AMBULATORY CENTER & HOME CARE
BY REGION, 2020 TO 2027 (USD MILLION) 43
TABLE 14 GLOBAL CARDIOVASCULAR APPLICATION MARKET FOR ACADEMIC CENTERS BY REGION,
2020 TO 2027 (USD MILLION) 44
TABLE 15 GLOBAL CARDIOVASCULAR APPLICATION MARKET BY REGION, 2020 TO 2027 (USD MILLION) 46
TABLE 16 AMERICAS CARDIOVASCULAR APPLICATION MARKET BY REGION, 2020 TO 2027 (USD MILLION) 48
TABLE 17 AMERICAS CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 48
TABLE 18 AMERICAS CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 48
TABLE 19 AMERICAS CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 49
TABLE 20 AMERICAS IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 49
TABLE 21 AMERICAS CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 49
TABLE 22 AMERICAS CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 50
TABLE 23 NORTH AMERICA CARDIOVASCULAR APPLICATION MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 51
TABLE 24 NORTH AMERICA CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 51
TABLE 25 NORTH AMERICA CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 51
TABLE 26 NORTH AMERICA CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 52
TABLE 27 NORTH AMERICA IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY,
2020 TO 2027 (USD MILLION) 52
TABLE 28 NORTH AMERICA CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 52
TABLE 29 NORTH AMERICA CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 53
TABLE 30 U.S. CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 53
TABLE 31 U.S. CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 54
TABLE 32 U.S. CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 54
TABLE 33 U.S. IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 54
TABLE 34 U.S. CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 55
TABLE 35 U.S. CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 55
TABLE 36 CANADA CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 56
TABLE 37 CANADA CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 56
TABLE 38 CANADA CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 56
TABLE 39 CANADA IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 57
TABLE 40 CANADA CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 57
TABLE 41 CANADA CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 58
TABLE 42 SOUTH AMERICA CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 58
TABLE 43 SOUTH AMERICA CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 59
TABLE 44 SOUTH AMERICA CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 59
TABLE 45 SOUTH AMERICA IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY,
2020 TO 2027 (USD MILLION) 59
TABLE 46 SOUTH AMERICA CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 60
TABLE 47 SOUTH AMERICA CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 60
TABLE 48 EUROPE CARDIOVASCULAR APPLICATION MARKET BY REGION, 2020 TO 2027 (USD MILLION) 61
TABLE 49 EUROPE CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 62
TABLE 50 EUROPE CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 62
TABLE 51 EUROPE CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 62
TABLE 52 EUROPE IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 63
TABLE 53 EUROPE CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 63
TABLE 54 EUROPE CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 64
TABLE 55 WESTERN EUROPE CARDIOVASCULAR APPLICATION MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 65
TABLE 56 WESTERN EUROPE CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 65
TABLE 57 WESTERN EUROPE CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 66
TABLE 58 WESTERN EUROPE CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 66
TABLE 59 WESTERN EUROPE IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY,
2020 TO 2027 (USD MILLION) 66
TABLE 60 WESTERN EUROPE CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 67
TABLE 61 WESTERN EUROPE CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 67
TABLE 62 GERMANY CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 68
TABLE 63 GERMANY CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 68
TABLE 64 GERMANY CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 68
TABLE 65 GERMANY IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 69
TABLE 66 GERMANY CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 69
TABLE 67 GERMANY CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 70
TABLE 68 FRANCE CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 70
TABLE 69 FRANCE CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 71
TABLE 70 FRANCE CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 71
TABLE 71 FRANCE IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 71
TABLE 72 FRANCE CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 72
TABLE 73 FRANCE CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 72
TABLE 74 U.K. CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 73
TABLE 75 U.K. CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 73
TABLE 76 U.K. CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 73
TABLE 77 U.K. IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 74
TABLE 78 U.K. CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 74
TABLE 79 U.K. CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 75
TABLE 80 ITALY CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 75
TABLE 81 ITALY CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 76
TABLE 82 ITALY CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 76
TABLE 83 ITALY IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 76
TABLE 84 ITALY CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 77
TABLE 85 ITALY CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 77
TABLE 86 SPAIN CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 78
TABLE 87 SPAIN CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 78
TABLE 88 SPAIN CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 78
TABLE 89 SPAIN IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 79
TABLE 90 SPAIN CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 79
TABLE 91 SPAIN CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 80
TABLE 92 REST OF WESTERN EUROPE CARDIOVASCULAR APPLICATION MARKET BY DEVICE,
2020 TO 2027 (USD MILLION) 80
TABLE 93 REST OF WESTERN EUROPE CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 81
TABLE 94 REST OF WESTERN EUROPE CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 81
TABLE 95 REST OF WESTERN EUROPE IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY,
2020 TO 2027 (USD MILLION) 82
TABLE 96 REST OF WESTERN EUROPE CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 82
TABLE 97 REST OF WESTERN EUROPE CARDIOVASCULAR APPLICATION MARKET BY END USER,
2020 TO 2027 (USD MILLION) 83
TABLE 98 EASTERN EUROPE CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 83
TABLE 99 EASTERN EUROPE CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 84
TABLE 100 EASTERN EUROPE CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 84
TABLE 101 EASTERN EUROPE IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY,
2020 TO 2027 (USD MILLION) 84
TABLE 102 EASTERN EUROPE CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 85
TABLE 103 EASTERN EUROPE CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 85
TABLE 104 ASIA PACIFIC CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 87
TABLE 105 ASIA PACIFIC CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 88
TABLE 106 ASIA PACIFIC CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 88
TABLE 107 ASIA PACIFIC IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 88
TABLE 108 ASIA PACIFIC CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 89
TABLE 109 ASIA PACIFIC CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 89
TABLE 110 JAPAN CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 90
TABLE 111 JAPAN CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 90
TABLE 112 JAPAN CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 90
TABLE 113 JAPAN IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 91
TABLE 114 JAPAN CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 91
TABLE 115 JAPAN CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 92
TABLE 116 CHINA CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 92
TABLE 117 CHINA CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 93
TABLE 118 CHINA CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 93
TABLE 119 CHINA IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 93
TABLE 120 CHINA CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 94
TABLE 121 CHINA CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 94
TABLE 122 INDIA CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 95
TABLE 123 INDIA CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 95
TABLE 124 INDIA CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 95
TABLE 125 INDIA IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 96
TABLE 126 INDIA CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 96
TABLE 127 INDIA CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 97
TABLE 128 AUSTRALIA CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 97
TABLE 129 AUSTRALIA CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 98
TABLE 130 AUSTRALIA CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 98
TABLE 131 AUSTRALIA IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 98
TABLE 132 AUSTRALIA CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 99
TABLE 133 AUSTRALIA CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 99
TABLE 134 REPUBLIC OF KOREA CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 100
TABLE 135 REPUBLIC OF KOREA CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 100
TABLE 136 REPUBLIC OF KOREA CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 101
TABLE 137 REPUBLIC OF KOREA IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY,
2020 TO 2027 (USD MILLION) 101
TABLE 138 REPUBLIC OF KOREA CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 101
TABLE 139 REPUBLIC OF KOREA CARDIOVASCULAR APPLICATION MARKET BY END USER,
2020 TO 2027 (USD MILLION) 102
TABLE 140 REST OF ASIA PACIFIC CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 102
TABLE 141 REST OF ASIA PACIFIC CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 103
TABLE 142 REST OF ASIA PACIFIC CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 103
TABLE 143 REST OF ASIA PACIFIC IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY,
2020 TO 2027 (USD MILLION) 103
TABLE 144 REST OF ASIA PACIFIC CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 104
TABLE 145 REST OF ASIA PACIFIC CARDIOVASCULAR APPLICATION MARKET BY END USER,
2020 TO 2027 (USD MILLION) 104
TABLE 146 MIDDLE EAST & AFRICA CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 106
TABLE 147 MIDDLE EAST & AFRICA CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 107
TABLE 148 MIDDLE EAST & AFRICA CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 107
TABLE 149 MIDDLE EAST & AFRICA IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY,
2020 TO 2027 (USD MILLION) 107
TABLE 150 MIDDLE EAST & AFRICA CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 108
TABLE 151 MIDDLE EAST & AFRICA CARDIOVASCULAR APPLICATION MARKET BY END USER,
2020 TO 2027 (USD MILLION) 108
TABLE 152 UAE CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 109
TABLE 153 UAE CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 109
TABLE 154 UAE CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 109
TABLE 155 UAE IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 110
TABLE 156 UAE CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 110
TABLE 157 UAE CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 111
TABLE 158 SAUDI ARABIA CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 111
TABLE 159 SAUDI ARABIA CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 112
TABLE 160 SAUDI ARABIA CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 112
TABLE 161 SAUDI ARABIA IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY,
2020 TO 2027 (USD MILLION) 112
TABLE 162 SAUDI ARABIA CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 113
TABLE 163 SAUDI ARABIA CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 113
TABLE 164 OMAN CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 114
TABLE 165 OMAN CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 114
TABLE 166 OMAN CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 114
TABLE 167 OMAN IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 115
TABLE 168 OMAN CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 115
TABLE 169 OMAN CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 116
TABLE 170 KUWAIT CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 116
TABLE 171 KUWAIT CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 117
TABLE 172 KUWAIT CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 117
TABLE 173 KUWAIT IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 117
TABLE 174 KUWAIT CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 118
TABLE 175 KUWAIT CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 118
TABLE 176 QATAR CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 TO 2027 (USD MILLION) 119
TABLE 177 QATAR CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 119
TABLE 178 QATAR CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 119
TABLE 179 QATAR IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY, 2020 TO 2027 (USD MILLION) 120
TABLE 180 QATAR CARDIAC DEFIBRILLATOR MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 120
TABLE 181 QATAR CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 TO 2027 (USD MILLION) 121
TABLE 182 REST OF MIDDLE EAST & AFRICA CARDIOVASCULAR APPLICATION MARKET BY DEVICE,
2020 TO 2027 (USD MILLION) 121
TABLE 183 REST OF MIDDLE EAST & AFRICA CARDIAC MONITORS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 122
TABLE 184 REST OF MIDDLE EAST & AFRICA CARDIAC PACEMAKERS MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 122
TABLE 185 REST OF MIDDLE EAST & AFRICA IMPLANTABLE CARDIAC PACEMAKER MARKET BY TECHNOLOGY,
2020 TO 2027 (USD MILLION) 123
TABLE 186 REST OF MIDDLE EAST & AFRICA CARDIAC DEFIBRILLATOR MARKET BY TYPE,
2020 TO 2027 (USD MILLION) 123
TABLE 187 REST OF MIDDLE EAST & AFRICA CARDIOVASCULAR APPLICATION MARKET BY END USER,
2020 TO 2027 (USD MILLION) 124
14 List Of Figures
FIGURE 1 GLOBAL CARDIOVASCULAR APPLICATION MARKET, 2020 TO 2027 (USD MILLION) 14
FIGURE 2 GLOBAL CARDIOVASCULAR APPLICATION MARKET SHARE BY DEVICE, 2020 (%) 15
FIGURE 3 GLOBAL CARDIOVASCULAR APPLICATION MARKET SHARE BY END USER, 2020 (%) 15
FIGURE 4 GLOBAL CARDIOVASCULAR APPLICATION MARKET SHARE BY REGION, 2020 (%) 16
FIGURE 5 MARKET STRUCTURE OF GLOBAL CARDIOVASCULAR APPLICATION MARKET 18
FIGURE 6 RESEARCH METHODOLOGY 19
FIGURE 7 VALUE CHAIN: CORONARY PRESSURE MONITORS 23
FIGURE 8 PORTER’S FIVE FORCES MODEL 25
FIGURE 9 MAKRET DYNAMICS 28
FIGURE 10 GLOBAL CARDIOVASCULAR APPLICATION MARKET BY DEVICE, 2020 & 2027 (USD MILLION) 35
FIGURE 11 GLOBAL CARDIOVASCULAR APPLICATION MARKET BY END USER, 2020 & 2027 (USD MILLION) 40
FIGURE 12 GLOBAL CARDIOVASCULAR APPLICATION MARKET BY REGION, 2020 & 2027 (USD MILLION) 45
FIGURE 13 AMERICA CARDIOVASCULAR APPLICATION MARKET SHARE BY REGION, 2020 (%) 47
FIGURE 14 NORTH AMERICA CARDIOVASCULAR APPLICATION MARKET SHARE BY COUNTRY, 2020 (%) 50
FIGURE 15 EUROPE CARDIOVASCULAR APPLICATION MARKET SHARE BY REGION, 2020 (%) 61
FIGURE 16 WESTERN EUROPE CARDIOVASCULAR APPLICATION MARKET SHARE BY COUNTRY, 2020 (%) 64
FIGURE 17 ASIA PACIFIC CARDIOVASCULAR APPLICATION MARKET SHARE BY REGION, 2020 (%) 86
FIGURE 18 ASIA PACIFIC CARDIOVASCULAR APPLICATION MARKET BY REGION, 2020 TO 2027 (USD MILLION) 87
FIGURE 19 MIDDLE EAST & AFRICA CARDIOVASCULAR APPLICATION MARKET SHARE BY REGION, 2020 (%) 105
FIGURE 20 MIDDLE EAST & AFRICA CARDIOVASCULAR APPLICATION MARKET BY REGION,
2020 TO 2027 (USD MILLION) 106
FIGURE 21 GOBAL CARDIOVASCULAR APPLICATION MARKET, COMPANY SHARE ANALYSIS, 2020 (%) 125